• Daré Bioscience reported peer-reviewed publication of Phase 1 results for topical Sildenafil Cream, 3.6% in healthy men.
• Results were already presented via the journal article in Sexual Medicine.
• Study showed substantially lower systemic exposure with topical dosing versus oral sildenafil, supporting a localized delivery profile.
• Treatments were generally well tolerated, with only mild adverse events reported and no serious safety signals.
• Data underpin continued development for women’s sexual health, including a dose later used in a Phase 2b study in women.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dare Bioscience Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609140850PRIMZONEFULLFEED9825762) on September 14, 2026, and is solely responsible for the information contained therein.